Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a globally diversified conglomerate based in Washington, D.C., focusing primarily on life sciences and diagnostics. Founded in 1984 by Stephen and Mitchell Rales, the company has transitioned from a real estate organization into a leading player in the medical, industrial, and commercial products sectors.
Danaher designs, manufactures, and markets a variety of innovative products, particularly scientific instruments and consumables. The company has recently revamped its portfolio by divesting its environmental and applied solutions group, Veralto, in late 2023. This strategic move has allowed Danaher to concentrate its efforts on advancing health through science and technology.
Among Danaher's notable achievements is the acquisition of Abcam plc, which enhances its capabilities in proteomics—an expanding field within life sciences. The company is also known for its contribution to gene-editing therapies through a collaboration with the Innovative Genomics Institute (IGI), aiming to develop CRISPR-based treatments for various diseases.
Danaher's portfolio includes well-known subsidiaries like Beckman Coulter Life Sciences, Integrated DNA Technologies, and Aldevron. These subsidiaries focus on delivering innovative solutions in diagnostics, genomics, and biomanufacturing. For instance, Beckman Coulter's recent partnership with Curiox Biosystems aims to provide automated sample preparation for flow cytometry, enhancing research efficiency.
Financially, Danaher reported better-than-expected revenue in the fourth quarter of 2023, bolstered by strong performance in its life sciences and diagnostics segments. The company's strategic divestitures and acquisitions have positioned it for long-term growth and increased shareholder value.
Danaher’s ongoing projects include a collaboration with Cincinnati Children's Hospital to improve liver organoid technology for drug toxicity screening. This initiative is part of the Danaher Beacons program, which funds pioneering academic research to develop next-generation medical technologies. Another significant collaboration is with Johns Hopkins University, focusing on diagnosing mild traumatic brain injuries (TBI) using advanced biomarker panels.
Overall, Danaher's commitment to scientific excellence, innovation, and continuous improvement makes it a crucial player in advancing healthcare globally. With over 63,000 associates worldwide, Danaher is dedicated to improving quality of life and laying the groundwork for a healthier, more sustainable future.
Beckman Coulter announced its commitment to support the U.S. government's plan to invest over $12 billion in COVID-19 testing by providing a high-throughput, $4 antigen test, Access SARS-CoV-2 Ag, aimed at mass screening. This test boasts a 93% positive predictive agreement and a 100% negative predictive agreement, with results available in 30 minutes. Targeted for high-risk settings, the test promotes equity in COVID-19 testing and aids in reopening schools and businesses safely.
Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will present at the Barclays Global Healthcare Conference on March 11, 2021, at 11:30 a.m. ET. The presentation will be available via a simultaneous webcast on Danaher's official website.
Danaher is a leading global innovator in science and technology, focusing on complex challenges in healthcare, environmental, and applied markets. The company employs around 69,000 associates and operates more than 20 companies under the Danaher Business System.
On February 23, 2021, Danaher Corporation (NYSE: DHR) announced the approval of a quarterly cash dividend of $0.21 per share for common stock, payable on April 30, 2021, to shareholders of record by March 26, 2021. Additionally, the company approved dividends for its preferred stock, including $11.875 per share for 4.75% Series A and $12.50 per share for 5.00% Series B, both payable on April 15, 2021, to holders of record by March 31, 2021.
Danaher Corporation (NYSE: DHR) announced that its President and CEO, Rainer M. Blair, will speak at the Cowen Healthcare Conference on March 1, 2021, at 11:40 a.m. ET. The presentation will be accessible via a live webcast on www.danaher.com. Danaher is a prominent global innovator in science and technology, focusing on solving complex challenges in healthcare and other sectors, supported by its diverse workforce of about 69,000 associates.
Cytiva has acquired Vanrx Pharmasystems, a Canadian firm specializing in robotic aseptic filling machines, marking its first acquisition since becoming an operating company of Danaher in April 2020. This acquisition aligns with global trends towards smaller batch manufacturing and personalized therapies in the growing USD 300 billion biologics market. The addition enhances Cytiva's solutions from drug development to drug product, facilitating faster delivery of therapies to patients. Vanrx's expertise in aseptic filling complements Cytiva's existing manufacturing capabilities.
Danaher Corporation (NYSE: DHR) reported strong financial results for Q4 and full year 2020. Q4 net earnings reached $1.2 billion ($1.66 per share), up 55% year-over-year, while revenues climbed 39% to $6.8 billion. Full year net earnings totaled $3.6 billion ($4.89 per share), reflecting a 50% increase, with total revenues at $22.3 billion, a 24.5% rise. The company anticipates mid to high-teens non-GAAP core revenue growth for Q1 2021 and low-double digits for the full year. The acquisition of Cytiva significantly bolstered Danaher's market position and long-term value.
Beckman Coulter announced the launch of the DxH 560 AL, a compact tabletop analyzer designed for small to mid-sized laboratories. This innovative device features Auto-Loading functionality, allowing for continuous sample addition of up to 50, while minimizing manual tasks and resource usage. It requires only 17 μL of blood, making it ideal for difficult-to-draw patients, and delivers results in under 60 seconds. The DxH 560 AL aims to provide large laboratory efficiency at a lower cost, enhancing productivity without exceeding budgetary constraints.
Beckman Coulter announced the launch of the DxH 560 AL, a tabletop analyzer designed for small to mid-sized laboratories. This innovative device features auto-loading functionality, accommodating up to 50 samples and requiring only a 17 μL sample volume, among the lowest in the market. The DxH 560 AL provides results in under 60 seconds, enhancing efficiency. It also includes advanced security features for patient data protection. The analyzer is part of the DxH 500 series, offering high-throughput capabilities while remaining budget-friendly.
On January 13, 2021, Danaher Corporation (NYSE: DHR) announced strong financial performance for Q4 2020 during the J.P. Morgan Healthcare Conference. The company expects core revenue growth, including Cytiva, to exceed previous guidance, driven by robust results in Life Sciences and Diagnostics segments. Estimated revenues rose approximately 38.5% year-over-year, with non-GAAP core revenue growth estimated at 15%. Danaher will report full earnings on January 28, 2021.
Danaher Corporation (NYSE: DHR) will have its President and CEO, Rainer M. Blair, present at the J.P. Morgan Healthcare Conference on January 13, 2021, at 10:50 a.m. ET. This presentation will be available via a live audio webcast and will be archived for later access on Danaher’s website.
As a leader in science and technology, Danaher focuses on solving complex challenges across healthcare and environmental markets, employing over 67,000 associates committed to improving quality of life globally.
FAQ
What is the current stock price of Danaher Corporation (DHR)?
What is the market cap of Danaher Corporation (DHR)?
What does Danaher Corporation specialize in?
Who founded Danaher Corporation and when?
Where is Danaher Corporation headquartered?
What recent divestiture has Danaher Corporation made?
What are some of Danaher's notable subsidiaries?
What recent acquisition has enhanced Danaher's capabilities in proteomics?
What is the Danaher Beacons program?
What collaboration is Danaher involved in to improve liver organoid technology?
What is the focus of Danaher's partnership with Johns Hopkins University?
How does Danaher contribute to the field of gene-editing therapies?
